Phase I/II proof of concept trial of HemaXellerate™ I in patients with treatment resistant aplastic anaemia.

Trial Profile

Phase I/II proof of concept trial of HemaXellerate™ I in patients with treatment resistant aplastic anaemia.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 May 2016

At a glance

  • Drugs HemaXellerate I (Primary)
  • Indications Aplastic anaemia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Regen BioPharma
  • Most Recent Events

    • 11 May 2016 According to Regen media release, the Company intends to amend its previously submitted Investigational New Drug Application for HemaXellerate in order that Regen may obtain consent from the United States Food and Drug Administration (FDA) to pursue this trial.
    • 15 Dec 2015 According to Regen BioPharma Inc media release, the US FDA has granted clearance to initiate clinical trial for HemaXellerate-1 in refractory aplastic anemia.
    • 15 Dec 2015 Status changed from planning to not yet recruiting, as per a Regen BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top